Stocks Recap: Companhia de Bebidas das Americas, Clearwire Corporation, Stryker Corporation, ZIOPHARM Oncology Inc

Lakeway, TX -- (SBWIRE) -- 03/04/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Companhia de Bebidas das Americas (ADR) (NYSE:ABV) stock gained 1.62% to $45.10. The company, on Feb. 26, announced that, on February 25, 2013, its Board of Directors approved the distribution of dividend to be imputed to the obligatory minimum dividend for the 2012 fiscal year at the value of BRL 0.568 per ordinary share and BRL 0.6248 per preferred share. It also approved own capital interest to be imputed to the minimum obligatory dividend for the 2013 fiscal year at the value of BRL 0.08 per ordinary share (net value of BRL 0.068 per share) and BRL 0.088 per preferred share (net value of BRL 0.0748 per share).

How Should Investors Trade ABV After The Recent Movement? Find Out Here

Clearwire Corporation (NASDAQ:CLWR) shares jumped 1.60% and closed at $3.18 in the last trading session. The company, on Feb. 27, announced that it has elected to take the $80 million March draw under the terms of its agreements with Sprint Nextel Corporation ("Sprint") that provide additional financing to Clearwire in the form of exchangeable notes, which will be exchangeable under certain conditions for Clearwire common stock at $1.50 per share, subject to adjustment under certain conditions. Clearwire no longer has any right to take the first two monthly draws under the Sprint Financing Agreements.

Is CLWR Strong Buy After The Recent Strong Gains? Get Free Trend Analysis Here

Stryker Corporation (NYSE:SYK) shares gained 1.60% to $64.90. The company, on Feb. 13, announced that its Board of Directors has declared a quarterly dividend of $0.265 per share payable on April 30, 2013, to shareholders of record at the close of business on March 29, 2013, representing an increase of 25% versus the prior year.

Is SYK a Buying Opportunity After The Recent Plunge? Don’t Miss Out Our Latest Report Here

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares climbed 1.58% and closed at $4.51. The company, on Feb. 12, announced that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS.

How Should Investors Trade ZIOP After The Latest Earnings Report? Find Out Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.